The Recce 327 Topical Gel is “highly effective” for treating infected burn wounds – and it works quickly too – Recce Pharmaceuticals (ASX:RCE) confirmed in ongoing tests, setting the stage for a U.S. Defence partnership.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This content is disseminated in partnership with Recce. It is intended to inform investors and should not be taken as a recommendation or financial advice.
While a pivot into State-side defence may be surprising for some Recce shareholders, it forms part of a larger strategy that the company is very confident will yield promising results relatively shortly.
The biotech player’s confidence boils down to one thing: It’s “superior” to other options.
“Our compound is statistically significant in its ability to reduce the infections above and beyond the existing forms of treatment, and statistically superior to be able to close those infections or have wound healing,” Recce’s CEO, James Graham, told HotCopper in a Watchlist interview soon after the release.
“It’s a very, very complicated space, and so this is very promising,” he added.
With these results in pocket, RCE is now looking to use its “new hope” to partner with the U.S. Department of Defence and secure more windfall grants; that U.S. defence arm has been calling for companies to help in the space.
There’s a track record set here, too: Recce previously netted a $2M U.S. Army grant.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)